Loading...

We've got a brand new version of Simply Wall St! Try it out

Orion Nutraceuticals

CNSX:ORI
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ORI
CNSX
CA$5M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Orion Nutraceuticals Inc., a cannabis life science company, focuses on the production and distribution of medicinal and recreational cannabinoid oil and extracts for the sports medicine market in Canada. The last earnings update was 174 days ago. More info.


Add to Portfolio Compare Print
ORI Share Price and Events
7 Day Returns
0%
CNSX:ORI
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-
CNSX:ORI
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
ORI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Orion Nutraceuticals (ORI) 0% 58.3% 35.7% - - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on ORI.
  • No trading data on ORI.
Price Volatility
Industry
5yr Volatility vs Market

ORI Value

 Is Orion Nutraceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Orion Nutraceuticals. This is due to cash flow or dividend data being unavailable. The share price is CA$0.095.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Orion Nutraceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Orion Nutraceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:ORI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-02-28) in CAD CA$-0.12
CNSX:ORI Share Price ** CNSX (2019-09-17) in CAD CA$0.1
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Orion Nutraceuticals.

CNSX:ORI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:ORI Share Price ÷ EPS (both in CAD)

= 0.1 ÷ -0.12

-0.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orion Nutraceuticals is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Orion Nutraceuticals is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Orion Nutraceuticals's expected growth come at a high price?
Raw Data
CNSX:ORI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.79x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Orion Nutraceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Orion Nutraceuticals's assets?
Raw Data
CNSX:ORI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-02-28) in CAD CA$0.09
CNSX:ORI Share Price * CNSX (2019-09-17) in CAD CA$0.1
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:ORI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:ORI Share Price ÷ Book Value per Share (both in CAD)

= 0.1 ÷ 0.09

1.04x

* Primary Listing of Orion Nutraceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orion Nutraceuticals is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Orion Nutraceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Orion Nutraceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ORI Future Performance

 How is Orion Nutraceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orion Nutraceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Orion Nutraceuticals expected to grow at an attractive rate?
  • Unable to compare Orion Nutraceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Orion Nutraceuticals's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Orion Nutraceuticals's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:ORI Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:ORI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:ORI Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-02-28 -2 -2
2018-05-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Orion Nutraceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if Orion Nutraceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:ORI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Orion Nutraceuticals Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ORI Past Financials Data
Date (Data in CAD Millions) EPS *
2019-02-28 -0.12
2018-05-31 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Orion Nutraceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Orion Nutraceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Orion Nutraceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Orion Nutraceuticals's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Orion Nutraceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Orion Nutraceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ORI Past Performance

  How has Orion Nutraceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Orion Nutraceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Orion Nutraceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Orion Nutraceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Orion Nutraceuticals's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Orion Nutraceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Orion Nutraceuticals Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ORI Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-02-28 -1.99 1.80
2018-05-31 -0.35 0.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Orion Nutraceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Orion Nutraceuticals has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Orion Nutraceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Orion Nutraceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Orion Nutraceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ORI Health

 How is Orion Nutraceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Orion Nutraceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Orion Nutraceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Orion Nutraceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Orion Nutraceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Orion Nutraceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Orion Nutraceuticals Company Filings, last reported 6 months ago.

CNSX:ORI Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-02-28 4.26 0.00 0.02
2018-05-31 1.18 0.00 0.35
  • Orion Nutraceuticals has no debt.
  • Orion Nutraceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Orion Nutraceuticals has less than a year of cash runway based on current free cash flow.
  • Orion Nutraceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 220.1% each year.
X
Financial health checks
We assess Orion Nutraceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Orion Nutraceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ORI Dividends

 What is Orion Nutraceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Orion Nutraceuticals dividends.
If you bought CA$2,000 of Orion Nutraceuticals shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Orion Nutraceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Orion Nutraceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:ORI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Orion Nutraceuticals has not reported any payouts.
  • Unable to verify if Orion Nutraceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Orion Nutraceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Orion Nutraceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Orion Nutraceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Orion Nutraceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Orion Nutraceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ORI Management

 What is the CEO of Orion Nutraceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joel Dumaresq
AGE 53
TENURE AS CEO 0.1 years
CEO Bio

Mr. Joel S. Dumaresq has been Chief Executive Officer and Director of Orion Nutraceuticals Inc. since August 2019. He serves as Director at Experion Holdings Ltd. Since June 07, 2019. He has been Chief Executive Officer at Organic Flower Investments Group Inc. since March 13, 2019. He serves as an Additional Director at Organic Flower Investments Group Inc. since joining the firm in October 15, 2018. Mr. Dumaresq has been Chief Financial Officer of Black Isle Resources Corporation since June 1, 2018. Mr. Dumaresq is Additional Director at Vancouver, British Columbia since October 10, 2018. He served as a Director at Admiral Bay Resources Inc. from June 13, 2018 to December 14, 2018. Mr. Dumaresq has been the Chief Executive Officer at Molori Energy Inc. since April 11, 2016. Mr. Dumaresq has been the Chief Financial Officer at 1Inc. since May 2013. Mr. Dumaresq has been the Chief Financial Officer of Eastern Zinc Corp. since September 15, 2011. Mr. Dumaresq serves as a Principal, Managing Director and Partner at Pashleth Merchant Capital Corp. He served as Chief Executive Officer and President at Sora Capital Corp. from January 27, 2011 until July 07, 2011. He served as the Chief Financial Officer at Molori Energy Inc. from April 11, 2013 until April 5, 2016. He served as Business Advisor of Greenscape Capital Group Inc. He was a Co-Founder and Partner of Matrix Partners Inc. He served as the Chief Executive Officer and President at Sojourn Ventures Inc. until June 2017. Mr. Dumaresq served as Managing Director for several years at Matrix Partners Inc. He served as the President of Greenwater Forest Products. He served as the Chief Financial Officer and Secretary of Shelby Ventures Inc., from December 5, 2007 to December 30, 2010. He served as the President and Chief Executive Officer of MegumaGold Corp. (formerly known as Coronet Metals Inc.) until June 1, 2011 and until September 27, 2012 respectively. Mr. Dumaresq served as the Chief Executive Officer and President of Black Smoker Ventures Inc., from January 27, 2011 to July 07, 2011. He served as the President and Secretary of Ebony & Gold Ventures, Inc. He served as the President of Solar Energy Ltd., until November 26, 2001. From 1994 to 1998, he served as the President of Westair Aviation Inc. He worked in financial services for RBC Dominion Securities Limited from 1986 to 1995. He served at the Verus Group on public equity financings and mergers and acquisitions. He served as the Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer of Planktos Corp., since July 22, 2008. He works at Cardinal Minerals Inc. Mr. Dumaresq was an Owner of Greenwater Forest Products Ltd. He served as the Chief Executive Officer and Director of Kariana Resources Inc. from February 28, 2012 to May 21, 2013. He serves as Chairman of 1Inc. He served as a Director of Solar Gold Ltd. since March 13, 2007. He served as the Chairman of the Board of Coronet Metals Inc. until June 07, 2016 and as its Director from July 15, 2010 to June 2016. He served as Non-Executive Chairman of Jager Resources Inc. (known as Worldwide Promotional Products Corp.) from July 2011 until October 10, 2013. He served as Non-Executive Chairman of Sora Capital Corp. from July 2011 until October 10, 2013. He served as the Chairman of Paramount Pallet Inc., since June 2005. He served as the Chairman of Parkit Enterprise Inc. from January 29, 2015 until May 29, 2018. He serves as Chairman at Molori Energy Inc. and has been a Director since April 5, 2016. He has been Director of Black Isle Resources Corporation since April 2018. He has been a Director of Booktech.com Inc., since January 17, 2000. He served as a Director of Parkit Enterprise Inc. from January 29, 2015 until May 29, 2018. Mr. Dumaresq has been a Director of Shelby Ventures Inc. since February 27, 2007 and Worldwide Promotional Products Corp. since July 5, 2010. He serves as a Director of Wattage Monitor Inc. and Smartsources.com. He has been a Director of Jager Resources Inc since July 05, 2010. He serves as Chairman of Eastern Zinc Corp. since March 31, 2019 and has been its Director since September 15, 2011. He served as a Director of Paramount Pallet, Inc. He served as Director of Sora Capital Corp. from July 05, 2010 until October 10, 2013. He has been a Director of ArcWest Exploration Inc. (formerly known as Sojourn Exploration Inc.) since December 23, 2010. He served as a Director of Ebony & Gold Ventures, Inc. since 2000 and Natcore Technology, Inc., until May 8, 2009. He served as a Director of Greenwater Forest Products Ltd. from April 1995 to June 2006. He serves as Director of Cervantes Capital Corp. since February 2018. He served as a Director of Solar Energy Ltd., and Syracuse Capital Corp.Mr. Dumaresq is an experienced business executive and investment specialist and his experience ranges from running public and private corporations to working for a national investment-banking firm. He also has managed controlling interests in a range of private and public enterprises world-wide. He has experience in the finance sector and also has M &A expertise. Mr. Dumaresq is a recipient of one of Canada’s highest civilian awards for bravery, the Star of Courage. He is a former Chair of the British Columbia chapter of the Young Presidents Organization and sits on the Board of Trustees of the Vancouver Police Foundation. Mr. Dumaresq holds a BA degree from the University of British Columbia in Economics and Psychology. He has operational and senior management experience in the forestry, mining and energy spaces.

CEO Compensation
  • Insufficient data for Joel to compare compensation growth.
  • Insufficient data for Joel to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Joel Dumaresq

TITLE
CEO & Director
AGE
53
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure of the Orion Nutraceuticals board of directors in years:

0.8
Average Tenure
  • The average tenure for the Orion Nutraceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Joel Dumaresq

TITLE
CEO & Director
AGE
53
TENURE
0.1 yrs

Robin Linden

TITLE
Director
TENURE
1.7 yrs

Matthew Bennett

TITLE
Member of Advisory Board
TENURE
0.8 yrs

Shannon Ford-Smith

TITLE
Member of Advisory Board
TENURE
0.8 yrs

Clarice Thomas

TITLE
Member of Advisory Board
TENURE
0.7 yrs

Sam Jenkins

TITLE
Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
03. Oct 18 Buy Accrete Consulting Inc Company 02. Oct 18 02. Oct 18 480,000 CA$0.25 CA$120,000
03. Oct 18 Buy Marcelin O'Neill Individual 02. Oct 18 02. Oct 18 1,520,000 CA$0.25 CA$42,500
29. May 19 Sell Jonathan Fiteni Individual 18. Oct 18 18. Oct 18 -4,000 CA$0.75 CA$-3,000
29. May 19 Buy Jonathan Fiteni Individual 25. Oct 18 15. Apr 19 188,500 CA$0.62 CA$54,326
14. Nov 18 Buy Jonathan Fiteni Individual 22. Oct 18 14. Nov 18 35,000 CA$0.81 CA$22,737
X
Management checks
We assess Orion Nutraceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Orion Nutraceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ORI News

Simply Wall St News

ORI Company Info

Description

Orion Nutraceuticals Inc., a cannabis life science company, focuses on the production and distribution of medicinal and recreational cannabinoid oil and extracts for the sports medicine market in Canada. It focuses on growing cannabis and extracting cannabis oil for use as an ingredient in proprietary health and beauty products, as well as distributed in bulk to other manufacturers. Orion Nutraceuticals Inc. has various professional sports strategic alliances. The company was formerly known as Cline Capital Corp. Orion Nutraceuticals Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Details
Name: Orion Nutraceuticals Inc.
ORI
Exchange: CNSX
Founded: 2017
CA$4,603,421
48,457,067
Website: http://www.orionnutra.ca
Address: Orion Nutraceuticals Inc.
1055 West Hastings Street,
Suite 300,
Vancouver,
British Columbia, V6E 2E9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX ORI Common Shares Canadian National Stock Exchange CA CAD 17. Oct 2018
OTCPK ORON.F Common Shares Pink Sheets LLC US USD 17. Oct 2018
DB 86O Common Shares Deutsche Boerse AG DE EUR 17. Oct 2018
Number of employees
Current staff
Staff numbers
0
Orion Nutraceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 01:02
End of day share price update: 2019/09/17 00:00
Last earnings filing: 2019/04/01
Last earnings reported: 2019/02/28
Last annual earnings reported: 2018/05/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.